MorphoSys EBITDA vs. Revenue

Based on MorphoSys' profitability indicators, MorphoSys AG ADR may not be well positioned to generate adequate gross income at the moment. It has a very high risk of underperforming in January. Profitability indicators assess MorphoSys' ability to earn profits and add value for shareholders.
For MorphoSys profitability analysis, we use financial ratios and fundamental drivers that measure the ability of MorphoSys to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well MorphoSys AG ADR utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between MorphoSys's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of MorphoSys AG ADR over time as well as its relative position and ranking within its peers.
  
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons.
Please note, there is a significant difference between MorphoSys' value and its price as these two are different measures arrived at by different means. Investors typically determine if MorphoSys is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, MorphoSys' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

MorphoSys AG ADR Revenue vs. EBITDA Fundamental Analysis

Comparative valuation techniques use various fundamental indicators to help in determining MorphoSys's current stock value. Our valuation model uses many indicators to compare MorphoSys value to that of its competitors to determine the firm's financial worth.
MorphoSys AG ADR is rated below average in ebitda category among its peers. It is regarded second in revenue category among its peers . Comparative valuation analysis is a catch-all technique that is used if you cannot value MorphoSys by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.

MorphoSys Revenue vs. EBITDA

EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.

MorphoSys

EBITDA

 = 

Revenue

-

Basic Expenses

 = 
(97.74 M)
In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.
Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.

MorphoSys

Revenue

 = 

Money Received

-

Discounts and Returns

 = 
238.28 M
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include products or services discounts, promotions, as well as early payments on invoices or services rendered in advance.

MorphoSys Revenue vs Competition

MorphoSys AG ADR is regarded second in revenue category among its peers. Market size based on revenue of Health Care industry is now estimated at about 671.62 Million. MorphoSys totals roughly 238.28 Million in revenue claiming about 35% of equities under Health Care industry.

MorphoSys Profitability Projections

The most important aspect of a successful company is its ability to generate a profit. For investors in MorphoSys, profitability is also one of the essential criteria for including it into their portfolios because, without profit, MorphoSys will eventually generate negative long term returns. The profitability progress is the general direction of MorphoSys' change in net profit over the period of time. It can combine multiple indicators of MorphoSys, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
MorphoSys AG, a commercial-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic antibodies for patients suffering from cancer and autoimmune diseases in the United States. The company was founded in 1992 and is headquartered in Planegg, Germany. Morphosys operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 648 people.

MorphoSys Profitability Driver Comparison

Profitability drivers are factors that can directly affect your investment outlook on MorphoSys. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of MorphoSys position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the MorphoSys' important profitability drivers and their relationship over time.

Use MorphoSys in pair-trading

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if MorphoSys position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in MorphoSys will appreciate offsetting losses from the drop in the long position's value.

MorphoSys Pair Trading

MorphoSys AG ADR Pair Trading Analysis

The ability to find closely correlated positions to MorphoSys could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace MorphoSys when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back MorphoSys - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling MorphoSys AG ADR to buy it.
The correlation of MorphoSys is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as MorphoSys moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if MorphoSys AG ADR moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for MorphoSys can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Use Investing Themes to Complement your MorphoSys position

In addition to having MorphoSys in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Candy and Soda Thematic Idea Now

Candy and Soda
Candy and Soda Theme
Fama and French investing themes focus on testing asset pricing under different economic assumptions. The Candy and Soda theme has 13 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Candy and Soda Theme or any other thematic opportunities.
View All  Next Launch
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons.
You can also try the Portfolio Backtesting module to avoid under-diversification and over-optimization by backtesting your portfolios.

Other Consideration for investing in MorphoSys Stock

If you are still planning to invest in MorphoSys AG ADR check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the MorphoSys' history and understand the potential risks before investing.
AI Portfolio Architect
Use AI to generate optimal portfolios and find profitable investment opportunities
Portfolio Center
All portfolio management and optimization tools to improve performance of your portfolios
Price Exposure Probability
Analyze equity upside and downside potential for a given time horizon across multiple markets
Analyst Advice
Analyst recommendations and target price estimates broken down by several categories
Price Transformation
Use Price Transformation models to analyze the depth of different equity instruments across global markets
Equity Valuation
Check real value of public entities based on technical and fundamental data
Sync Your Broker
Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.
Efficient Frontier
Plot and analyze your portfolio and positions against risk-return landscape of the market.
Pair Correlation
Compare performance and examine fundamental relationship between any two equity instruments